Coherus Provides Updates on Clinical Studies

Increases Enrollment in CHS-1701 Immunogenicity Study Initiated Enrollment in CHS-1420 Phase 3 Study REDWOOD CITY, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (NASDAQ:CHRS), a leading pure-play, global biosimilars company with late-stage...